Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 282

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 282
---
/28/2024 |     |                  |     — |     |               |   6,275 | -3 |     |          | 41.84 |     |            | 06/27/2034 |     |                 | — |     |          | — |

| (1) | The equity awards listed in the table above were granted under the 2023 Plan, the 2018 Plan, and the 2017 Plan. |

| (2) | The exercise prices do not reflect the Option Repricing. If the initial price to the public in this offering is                                                                                                                                        
 less than the exercise price of these options, then upon the execution of the underwriting agreement related to this offering, the exercise prices of these options will be automatically repriced to an exercise price per share equal to the initial 
 price per share to the public in this offering.                                                                                                                                                                                                        |

| (3) | 25% of the option vests upon the first anniversary of the grant date, and the remainder vests and becomes 
 exercisable in thirty-six (36) substantially equal monthly installments thereafter.                       |

| (4) | Resigned as our Chief Executive Officer in connection with Ms. Turner’s appointment as Chief Executive                                                                                                   
 Officer. In connection with such resignation, Mr. Prensky’s outstanding option awards were treated as described below under “—Potential Payments Upon Termination or Change in Control—Zachary Prensky.” |

| (5) | Was terminated from the Chief Financial Officer role in May 2025. In connection with such termination,                                                 
 Mr. Sawhney’s outstanding option award was treated as described below under “—Potential Payments Upon Termination or Change in Control—Roger Sawhney.” |

IPO Option Grants In September 2025, our board of directors approved the grant of options under our 2025 Plan to Ms. Turner and Dr. Eramo, effective upon the pricing of this offering, to purchase a number of shares of common stock such that their beneficial ownership of our total outstanding shares of capital stock as of the pricing date of this offering, on a fully diluted basis after giving effect to this offering, will be equal to approximately 4.5% and 192

0.75%, respectively. These options will have an exercise price equal to the initial public offering price. The shares underlying these options will vest as to 25% on the one-year anniversary of
the grant date, with the remainder vesting in 36 equal monthly install